Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First

  title={Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First},
  author={Carmine Zoccali and Francesca Romana Mallamaci and Giovanni Tripepi},
  journal={Seminars in Dialysis},
1. Coresh J, Wei GL, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health andNutrition Examination Survey (1988-1994).Arch InternMed 161:1207–1216, 2001 2. Agarwal R, Nissenson AR, Batlle D, et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. AmJMed 115:291–297, 2003 3. Agarwal R, Lewis RR: Prediction of hypertension in chronic… Expand

Topics from this paper

Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference.
This report summarizes the deliberations and recommendations of a conference sponsored by the Kidney Disease: Improving Global Outcomes (KDIGO) to address the following questions: what is the optimal BP treatment target in relation to end-organ damage and outcomes in dialysis patients; how should antihypertensive drugs be used in dial renal patients; and what nonpharmacological therapies can be considered in achieving BP targets. Expand
How should hypertension be assessed and managed in hemodialysis patients? Home BP, not dialysis unit BP, should be used for managing hypertension.
Outof-office BP measurement techniques in the management of patients on hemodialysis suggest that self-measured BP (home BP) recordings and ambulatory BP recordings reduce misclassification of hypertension and increase the ability to predict renal and cardiovascular events in patients with CKD. Expand


Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis.
Pulse pressure is associated with risk of death in a large, nationally representative sample of patients undergoing maintenance hemodialysis and the recognition of pulse pressure as an important correlate of mortality in patients receiving dialysis highlights the need to investigate the relationship between potential therapeutic implications of conduit vessel function and clinical outcomes in patients with end-stage renal disease. Expand
Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis.
The most favorable rate of progression of coronary atherosclerosis is observed in patients whose BP falls within the "normal" JNC-7 category, which suggests that in patients with coronary artery disease, the optimal BP goal may be substantially lower than the <140/90 mm Hg level. Expand
Blood pressure control in dialysis patients: importance of the lag phenomenon.
The lag phenomenon is described in detail, its presence during treatment in other populations is documented, and how this knowledge is used in the application of the dry-weight method of drug-free BP control in the dialysis population is described. Expand
Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients.
The results suggest that the night/day systolic ratio and LVH provide overlapping prognostic information, a phenomenon in keeping with the hypothesis that they represent a common pathway leading to adverse outcomes in ESRD. Expand
What is hypertension in chronic haemodialysis? The role of interdialytic blood pressure monitoring.
  • S. Mitra, S. Chandna, K. Farrington
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1999
Ambulatory monitoring has a role in evaluating persistent poor blood pressure control in haemodialysis patients andWalk-in predialysis pressures overestimate mean interdialytic pressures due to a high incidence of white-coat effect, which shows some habituation with time on dialysis. Expand
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
Trends were observed suggesting fosinopril may be associated with a lower risk of CVEs, and trends may have become statistically significant had the sample size been larger, and these findings warrant further study. Expand
Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease
In the setting of coronary care unit admission for CHF and ACS, ESRD patients selected forACE-I, did not have increased rates of adverse haemodynamic or arrhythmic complications and the use of ACE-I conferred an independent mortality reduction over long-term follow-up. Expand
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.
One year of therapy with carvedilol in dialysis patients with CHF and dilated cardiomyopathy reduces LV volumes and improves LV function and clinical status. Expand
Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses.
To evaluate the antihypertensive effects of lisinopril, a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) threeExpand
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure. Expand